ID: h-d3547d39c6
Hypothesis
Microglial NOX2 establishes an inflammatory ROS propagation loop around vulnerable neurons
Dying or stressed neurons release alpha-synuclein and DAMPs that activate microglia, which then generate superoxide through NOX2 and amplify TNF, IL1B, and NF-kB signaling.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Dying or stressed neurons release alpha-synuclein and DAMPs that activate microglia, which then generate superoxide through NOX2 and amplify TNF, IL1B, and NF-kB signaling. That extracellular ROS and cytokine field injures neighboring neurons, causing more aggregate release and renewed microglial activation. This best explains tissue-level spread and persistence rather than the earliest intracellular trigger.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["CYBB; NCF1; NCF2; RELA; NLRP3<br/>Primary Target"]
B["Biological Process 1<br/>Mechanistic Step A"]
C["Biological Process 2<br/>Mechanistic Step B"]
D["Output Phenotype<br/>Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
NOX2 is upregulated in PD substantia nigra and knockout models are protected from toxin-induced degeneration.
Supports
NOX2-derived ROS are required for alpha-synuclein-induced microglial activation and dopaminergic toxicity.
Supports
Specific NOX2 inhibitors show efficacy in neuroinflammatory models, supporting tractability.
Contradicts
Microglial activation may be secondary and better explains propagation than the initiating intracellular vicious cycle.
Contradicts
Protection in toxin models may overstate inflammatory dependence relative to idiopathic PD.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CYBB;
No curated PDB or AlphaFold mapping for CYBB; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CYBB; NCF1; NCF2; RELA; NLRP3 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CYBB; NCF1; NCF2; RELA; NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0038
Events (7d)
3
Price History
▼14.1%💾 Resource Usage
LLM Tokens
13,113
$0.0393
Total Cost
$0.0393
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF microglial NOX2 is selectively inhibited (pharmacologically with GKT137831 at 10 mg/kg/day i.p. or genetically via Cx3cr1-Cre conditional knockout of Cybb) in a mouse model of alpha-synuclein propa | Significant reduction in outward spread of oxidative DNA damage markers (8-OHdG+) and mitochondrial superoxide (mitoSOX) beyond the primary injection site, with | — no observation — | pending | 0.65 |
| IF NLRP3 inflammasome is genetically deleted (Nlrp3−/−) or pharmacologically inhibited (MCC950, 10 mg/kg/day i.p.) to interrupt the ROS-inflammasome feedback loop in a localized viral vector model of | Significant reduction in plasma IL-1β levels (ELISA, expected decrease from ~80 pg/mL in WT-vehicle to ≤40 pg/mL in Nlrp3−/− or MCC950-treated) and reduced micr | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF microglial NOX2 is selectively inhibited (pharmacologically with GKT137831 at 10 mg/kg/day i.p. or genetically via Cx3cr1-Cre conditional knockout of Cybb) in a mouse model of alpha-synuclein propagation (intracerebral injection of preformed alpha-synuclein fibrils, 5 μg per injection), THEN the
Predicted outcome: Significant reduction in outward spread of oxidative DNA damage markers (8-OHdG+) and mitochondrial superoxide (mitoSOX) beyond the primary injection
Falsification: NOX2 inhibition fails to reduce oxidative stress propagation; 8-OHdG+ cells or mitoSOX intensity in distal regions (≥500 μm from injection site) shows no significant difference (p>0.05, two-tailed t-t
pendingconf 55%
IF NLRP3 inflammasome is genetically deleted (Nlrp3−/−) or pharmacologically inhibited (MCC950, 10 mg/kg/day i.p.) to interrupt the ROS-inflammasome feedback loop in a localized viral vector model of alpha-synuclein overexpression (AAV9-hSyn-mCherry or AAV9-hSyn-αSyn-HA injected in left striatum), T
Predicted outcome: Significant reduction in plasma IL-1β levels (ELISA, expected decrease from ~80 pg/mL in WT-vehicle to ≤40 pg/mL in Nlrp3−/− or MCC950-treated) and re
Falsification: NLRP3 deletion or inhibition produces no significant reduction in contralateral microglial activation (Iba1+ CD68+ area fraction remains ≥10% with p>0.05 versus WT-vehicle) or plasma IL-1β levels (≤20
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.